BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27919998)

  • 1. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
    Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
    Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
    Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
    Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
    BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
    Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
    Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
    Jin F; Yang M; Chen Y; Jiang L; Liu L
    Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
    Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
    Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
    Chang H; Lee SY; Tang TC
    Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Terpos E; Politou M; Rahemtulla A
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
    Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Jaskiewicz AD; Herrington JD; Wong L
    Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
    Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysis syndrome in children with non-Hodgkin lymphoma.
    Alavi S; Arzanian MT; Abbasian MR; Ashena Z
    Pediatr Hematol Oncol; 2006; 23(1):65-70. PubMed ID: 16326415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
    Fassas AB; Desikan KR; Siegel D; Golper TA; Munshi NC; Barlogie B; Tricot G
    Br J Haematol; 1999 Jun; 105(4):938-41. PubMed ID: 10554803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
    Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
    Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
    Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of tumor lysis syndrome in 380 cases of acute leukemia].
    Zhang Q; Liu KQ; Liu BC; Zhou CL; Li W; Lin D; Wang Y; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):61-4. PubMed ID: 25687047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
    Montesinos P; Lorenzo I; Martín G; Sanz J; Pérez-Sirvent ML; Martínez D; Ortí G; Algarra L; Martínez J; Moscardó F; de la Rubia J; Jarque I; Sanz G; Sanz MA
    Haematologica; 2008 Jan; 93(1):67-74. PubMed ID: 18166787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
    Choi KA; Lee JE; Kim YG; Kim DJ; Kim K; Ko YH; Oh HY; Kim WS; Huh W
    Ann Hematol; 2009 Jul; 88(7):639-45. PubMed ID: 19030857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
    Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
    Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.